

## **PRESS RELEASE**

### **Opterion Health appoints Peter Reinemer as CEO**

**Muttenz, Switzerland, 18 January 2023** – Opterion Health AG, a Swiss-based life sciences company developing the first major innovation in peritoneal dialysis (PD) for two decades, today announced that Peter Reinemer has been appointed Chief Executive Officer. Currently Chief Technology Officer, Peter will assume the role of CEO in addition to his current position, with effect from 1<sup>st</sup> February 2023, replacing Björn Englund, who is leaving the company to take a leadership role at a major player in the field of dialysis.

Furthermore, Guido Grentzmann, who founded Opterion, has announced his decision to retire as Chief Scientific Officer at the end of March 2023. Guido will continue to support Opterion as an Advisor. Opterion plans to appoint a Chief Medical Officer in the future who will be supported by Guido.

“Peter brings huge expertise, experience and continuity to the role of CEO having played a critical part in the progress with the Osmotic Driver being developed by Opterion,” said David Ebsworth, Chairman of Opterion Health. “We are grateful to both Björn and to Guido for their outstanding contributions to the company’s success as we move towards achieving our goal of becoming a major provider of PD solutions. The handover to Peter is a sign of the strength and depth of our management team, and we wish Björn every success in his new venture and look forward to Guido’s sustained support and guidance in the coming years.”

Peter Reinemer has 30 years of experience in the pharmaceutical and biotechnology industries. He started his career at Bayer Pharma, where he worked for over 10 years in discovery research in Germany and Japan. Peter subsequently served as Chief Scientific Officer, Head of Business Development, Chief Operating Officer and Senior Vice President, Corporate Development, of Proteros, a discovery services company based in Munich and Boston. He is also a co-founder of IMD Natural Solutions, developer of the all-natural preservative agent Nagardo<sup>®</sup>, which was acquired by Lanxess AG in 2017. Peter holds a Master in Chemistry, a Ph.D. in Biochemistry with Robert Huber (Max-Planck-Institute for Biochemistry/TU Munich) and an MBA.

“It’s a great privilege to become CEO of Opterion Health at a pivotal stage in its development as we prepare the phase 1 study for our novel PD solution,” Peter Reinemer commented. “With a strong leadership team, great science and a genuinely innovative PD therapy with the potential to improve quality of life for patients, we can look forward with confidence to the future.”

**For more information, please contact:**

Beatrix Benz at [media@opterion.com](mailto:media@opterion.com) or +41 79 256 77 73

### **About Opterion Health AG**

Opterion Health was founded in 2012 by Guido Grentzmann with the goal of developing solutions to minimize the side effects of dialysis. The Company received strong financial backing from leading life science investors as of 2015 and has meanwhile built a strong team of scientists and entrepreneurs, supported by a network of nephrologists in Switzerland and Europe.

The company is developing a novel peritoneal dialysis (PD) solution, aiming to revolutionize the dialysis market. Animal studies have shown the superiority of the Opterion PD solution over the “gold standard” of the current market leader.

Opterion is based in MuttENZ, Switzerland. For more information, please visit [Opterion Health AG](#)